
Top stories

Marketing & Media#Loeries2025 and City of Cape Town drive creative industry
Danette Breitenbach 7 hours





More news























Energy & Mining
$4,000 an ounce: Gold price hits a record



This followed agreement with the Department of Health that the application complied with the criteria for fast-track review. Breakthroughs in immuno- oncology provide healthcare practitioners and patients with new options to treat cancer that did not exist before.
MSD has an extensive immuno-oncology clinical research programme, which currently involves more than 550 trials studying Pembrolizumab across a wide variety of cancers and treatment settings. MSD is currently working on making Pembrolizumab (trade name Keytruda) available to patients in early 2018.